Next Article in Journal
What mRNA Abundances Can Tell us about Metabolism
Previous Article in Journal
Minimal Cut Sets and the Use of Failure Modes in Metabolic Networks
Metabolites 2012, 2(3), 596-613; doi:10.3390/metabo2030596
Article

Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans

1,* , 2
, 2
, 1
, 1
 and 1
Received: 25 July 2012; in revised form: 21 August 2012 / Accepted: 29 August 2012 / Published: 11 September 2012
View Full-Text   |   Download PDF [331 KB, uploaded 11 September 2012]   |   Browse Figures
Abstract: STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS) and autism spectrum disorders (ASD). New clinical data in this article on the metabolism and pharmacokinetics of the R- and S-enantiomers of baclofen presents scientific evidence for stereoselective metabolism of only S-baclofen to an abundant oxidative deamination metabolite that is sterically resolved as the S-enantiomeric configuration. This metabolite undergoes some further metabolism by glucuronide conjugation. Consequences of this metabolic difference are a lower Cmax and lower early plasma exposure of S-baclofen compared to R-baclofen and marginally lower urinary excretion of S-baclofen after racemic baclofen administration. These differences introduce compound-related exposure variances in humans in which subjects dosed with racemic baclofen are exposed to a prominent metabolite of baclofen whilst subjects dosed with STX209 are not. For potential clinical use, our findings suggest that STX209 has the advantage of being a biologically defined and active enantiomer.
Keywords: pharmacokinetics; baclofen; R-baclofen; metabolic differentiation pharmacokinetics; baclofen; R-baclofen; metabolic differentiation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Sanchez-Ponce, R.; Wang, L.-Q.; Lu, W.; von Hehn, J.; Cherubini, M.; Rush, R. Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans. Metabolites 2012, 2, 596-613.

AMA Style

Sanchez-Ponce R, Wang L-Q, Lu W, von Hehn J, Cherubini M, Rush R. Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans. Metabolites. 2012; 2(3):596-613.

Chicago/Turabian Style

Sanchez-Ponce, Raymundo; Wang, Li-Quan; Lu, Wei; von Hehn, Jana; Cherubini, Maryann; Rush, Roger. 2012. "Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans." Metabolites 2, no. 3: 596-613.


Metabolites EISSN 2218-1989 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert